Causes of Visual Impairment Among Patients Applying for the Visually Disability Certification
Causes of Visual Impairment Among Patients Applying for the Visually Disability Certification in Upper Egypt: A Retrospective Study
Study Overview
Status
Conditions
Detailed Description
There are at least 2.2 billion individuals with near- or far-sightedness worldwide. Nearly half of these cases-at At least 1 billion-have untreated vision impairment that may have been avoided. The leading cause of blindness or impaired distant vision among these 1 billion people is diabetic retinopathy (3.9 million), age-related macular degeneration (8 million), cataracts (94 million), refractive error (88.4 million), and glaucoma (7.7 million). Presbyopia (826 million) is the primary ailment that impairs close vision.
According to estimates, there are four times as many cases of distant vision impairment in low- and middle-income areas as there are in high-income areas.
Aging populations and population expansion are predicted to raise the likelihood that more people may have visual impairment. Early on, irreversible severe visual impairment in young children can lead to delayed motor, verbal, emotional, social, and cognitive development, which can have long-term effects. Children of school age who are visually impaired may also perform less academically. The quality of life is significantly impacted by vision impairment in adult populations. Adults who are visually impaired may have greater rates of anxiety and depression as well as decreased employment rates.
Vision impairment in older persons can increase their risk of falling and breaking bones, walking difficulties, social isolation, and early admission into nursing homes or other care facilities.
According to estimates, vision impairment costs the world's economy $411 billion annually in lost productivity (purchasing power parity) . This amount is greatly above the predicted $25 billion cost gap incurred from treating vision impairment.
This study is to demonstrate the causes of visual impairment in upper Egypt among the different age groups and evaluate the possibility of preventing these disorders
Study Type
Enrollment (Actual)
Contacts and Locations
Study Locations
-
-
-
Asyut, Egypt, 33033
- Assiut University
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- All patients referred to The Ministry of Social Solidarity with visual Disability in upper Egypt who were examined in the visual disability screening program from 2020-2024.
Exclusion Criteria:
- The patients who had decreased vision but did not fit with the WHO definition of visual disability.
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The relative frequencies or prevalence of different eye diseases/conditions causing visual disability
Time Frame: 10 month
|
10 month
|
|
2-Ranking of the leading cause(s) of visual impairment
Time Frame: 10 month
|
10 month
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Neurologic Manifestations
- Nervous System Diseases
- Eye Diseases
- Sensation Disorders
- Pathological Conditions, Signs and Symptoms
- Signs and Symptoms
- Vision Disorders
- Musculoskeletal and Neural Physiological Phenomena
- Physiological Phenomena
- Evoked Potentials
- Cortical Excitability
- Electrophysiological Phenomena
- Nervous System Physiological Phenomena
- Ocular Physiological Phenomena
- Evoked Potentials, Visual
Other Study ID Numbers
- CVIAPAVDCUE
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.